Studies of association between use of proton pump inhibitors (PPI) and dementia have yielded conflicting results. We investigated the effects of PPIs on cognitive decline in a study of middleaged and elderly twins in Denmark.
P roton pump inhibitors (PPI) are a class of drugs commonly used in the treatment of gastroesophageal reflux disease and the healing and prevention of gastroduodenal ulcers. PPI use has increased markedly in recent years. 1, 2 In Denmark, 7.4% of all adults used PPIs in 2014. 2 The findings of 2 studies in Germany of a potential association between PPI use and increased risk of dementia 3, 4 gave rise to concern, 5 particularly because these drugs are more frequently used among older individuals, where the risk of dementia is high. Although preclinical data lend some support to the hypothesis of a detrimental effect of PPI on cognition (eg, through influencing b-amyloid levels in the brains of mice), 6 the evidence is equivocal. 7 To date, the results of epidemiologic studies have also been inconclusive, with more recent studies pointing toward a null association between PPI use and dementia. 8, 9 Current knowledge on the relationship between long-term PPI use and cognitive function, a predictor of the risk of dementia in later life, 10 is scant. 11 To investigate the association of long-term PPI use on changes in cognitive function over time, we used prospectively collected data from 2 large cohort studies conducted in Denmark where cognition was repeatedly assessed by trained interviewers, and information on PPI use was ascertained through a nationwide prescription register. Because the cohorts were recruited among Danish twins, we also investigated the association between PPI use and cognition among twin-pairs discordant with regard to cognitive decline, a powerful design to study the effects of nongenetic and noncommon environment exposures. 12 
Methods
For the purposes of this study, we linked data from surveys of Danish twins with nationwide register data as described in the following. The study was approved by the Danish Data Protection Agency and Statistics Denmark's Scientific Board. According to Danish law, approval from an ethics board and informed consent are not required for register studies.
Study Population and Data Linkage
The individuals in this study were identified among 9045 twins who participated in 1 of 2 population-based nationwide cohorts: the Longitudinal Study of Aging Danish Twins (LSADT), 13 and the Middle Age Danish Twin study (MADT).
14 Both studies were conducted through the nationwide Danish Twin Registry, which has covered all twin cohorts in the country since 1870. 15 Each survey comprised multidimensional interviews conducted by trained interviewers. All participants provided informed consent, and the Danish Scientific Ethics Committees approved both studies.
For each twin participating in LSADT, we used survey information from baseline (biannual waves, [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] and the 2-year follow-up. For MADT participants, we used information collected at baseline in 1998 and at follow-up 10 years later. For further details, see Supplementary Material.
Data from Danish Twin Registry were linked with information from population-based registers at Statistics Denmark. This included information from the Danish National Prescription Register (Prescription Registry), which holds information on all prescriptions for drugs dispensed at Danish community pharmacies since 1995 (Supplementary Material). 16 
Assessment of Exposure to Proton Pump Inhibitors
We used Prescription Register data to ascertain use of PPI among the twins. Each individual's cumulative use of PPI was calculated in defined daily doses (DDD) 17 as detailed in the Supplementary Material. Some PPIs are available without prescription in Denmark, but over-thecounter sales account for only 2% of the total volume.
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Assessment of Cognitive Functioning
Cognitive functioning at baseline and follow-up was assessed by a 5-component test battery. The test included a fluency test (number of animals named in 1 minute), forward digit span, backward digit span, and immediate and delayed recall of a 12-item list. Based on this information a composite cognitive score was calculated as a T-score by standardizing each single test to the mean and standard deviation of the values of the 45-49 year olds into a composite cognitive score, which was then linearly transformed to have a mean of 50 and a standard deviation of 10 in the youngest age group. This score has been used in a series of studies, and has been shown to be a valid, reliable, and very age-sensitive measure of cognitive functioning with high internal consistency reliability.
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Covariates Self-reported and register-based data were used to classify participants with regard to several disorders, and drug use patterns as listed in the statistical analyses section, and detailed in the Supplementary Methods, Supplementary Table 1 
Statistical Analysis
Descriptive statistics were expressed as means (standard deviations) or medians (interquartile range) for continuous variables and numbers and proportions for categorical variables.
We performed analyses for the overall cohorts (individual-based analyses), and for twin pairs where both twins in a pair participated (within-pair analyses). In each of these approaches we assessed the association between PPI use and cognitive functioning in crosssectional analyses and in longitudinal analyses.
Individual-based analyses. Comparisons of cognitive scores and PPI use were performed using multivariate linear regression. Outcome was cognitive score at baseline in cross-sectional analyses, and change in cognitive score from baseline to follow-up in the longitudinal analyses; negative values for each of these outcomes was indicative of participants on PPI attaining lower cognitive scores than nonusers of PPI. All models were adjusted for age; sex; body mass index; smoking; alcohol use; education level; history of depression, neurologic disorders (stroke, epilepsy, Parkinson disease), thyroid disorders, hypertension, diabetes; use of drugs with possible acute effects on cognition (strong analgesics, anxiolytic, antipsychotic drugs, or antidepressants); and use of statins, oral steroids, postmenopausal hormonereplacement therapy, low-dose aspirin, or nonsteroidal anti-inflammatory drugs, and ever use of histamine-2 receptor antagonists (H 2 RA). We adjusted for twin pair cluster effects (correlations) in all models to get unbiased confidence intervals (CIs). Cross-sectional analyses were also performed as stratified by age at baseline visit for both cohorts (below or above median age).
We performed supplementary analyses and tested for dose-response trend as outlined in the Supplementary Methods. Finally, prompted by recent reports, 11 we assessed the correlation between H 2 RA use and cognitive function in separate post hoc analyses with this class of drugs as the main exposure adjusted for potential confounders as described above and with the addition of PPI use (ever use [1þ prescriptions] vs never use [0 prescriptions]) to the model.
Within-pair analyses. Depending on zygosity, twins share 50% (dizygotic) to 100% (monozygotic) of their genetic material. To adjust for genetic and shared environmental confounding, we performed intrapair analyses limited to same sex pairs in which at least 1 of the twins had received PPI during follow-up. Among these twins we calculated the proportion (and corresponding 95% CI using the binomial distribution) of pairs in which the co-twin with the higher cumulative dose of PPI had the lowest cognitive score (cross-sectional analyses). For corresponding longitudinal analyses, we calculated the proportion of pairs with the largest decline in cognitive score. The null-hypothesis in all analyses was a proportion of pairs of 50%. The within-pair analyses are further detailed in the Supplementary Material.
Data were analyzed using STATA version 13.1 (StataCorp, College Station, TX).
Results
In all, baseline data on 7878 twins (MADT, n ¼ 4314; LSADT, n ¼ 3615) were available for cross-sectional analyses and 4821 participants for follow-up analyses (MADT, n ¼ 2346; LSADT, n ¼ 2475) ( Table 2 ). In the MADT, men had lower cognitive score than women (46.0 AE 10.2 vs 47.5 AE 10.1; P < .001). The cognitive scores of participants at baseline varied across strata of age in a predictable manner (Supplementary Table 3 ). A total of 262 (6%) of MADT twins and 299 (8.3%) of LSADT twins had used PPI in the 2-year period before baseline. Compared with nonexposed twins, participants with prebaseline use of PPI were slightly younger, did not differ in sex distribution, had attained a lower education level, and had slightly lower unadjusted mean composite cognitive scores at baseline in LSADT (34.5 vs 36.1; P < .05), but not in MADT (45.6 vs 46.8; P > .05) ( Table 1 ). In general, participants with prebaseline PPI use had a higher prevalence of comorbidities, and a more frequent use of medications other than PPI suggesting PPI users had a worse general health background status, compared with twins with no PPI use in the 2-year period before baseline.
Cross-sectional Analyses of Cognitive Score
Individual-based analyses. In MADT cohort, the adjusted difference in mean score of individuals with high prebaseline consumption of PPIs (!400 DDD) was lower than that of nonusers (mean crude score for high PPI use, 43.4 AE 13.1 vs for nonuse, 46.8 AE 10.2; adjusted difference of 0.69 points; 95% CI, À4.98 to 3.61). In LSADT cohort, individuals with high prebaseline PPI consumption had higher adjusted scores than nonusers (mean crude score for high PPI use, 35.2 AE 10.8 vs for nonuse, 36.2 AE 11.1; adjusted difference of 0.95 points; 95% CI, À1.88 to 3.79). Overall, cumulative dose of PPI within 2 years before baseline participation did not influence attained composite cognitive scores in either cohort (ie, LSADT or MADT) ( Table 2 ). An exception was a statistically significant difference in cognitive score among twins participating in LSADT who had been exposed to cumulative doses of 1-99 DDD of PPI and had lower cognitive scores compared with nonexposed twins f Defined as at least 1 filled prescription for the drug in question in the 2-year period preceding baseline.
g Defined as at least 1 filled prescription at any time preceding baseline (data available from 1995 onward). Within-pair analyses. There were 2693 intact twin pairs (ie, both twins in pair participated) with data on cognitive score at baseline. Of these 2083 were same sex pairs and 1800 of them did not differ with regard to PPI drug exposure, leaving 283 pairs for baseline intrapair analyses (MADT, 146 pairs; LSADT, 137 pairs).
Cumulative PPI use in the 2-year period before baseline did not influence cognitive score testing among twin pairs participating in LSADT, as measured by the proportion of twin pairs in which the twin exposed to higher cumulative PPI dose at baseline also was the twin with the lowest composite cognitive score (79 of 137 pairs, 58%; 95% CI, 49%-66%; P ¼ .087). However, this result was influenced by increasing the magnitude of intrapair difference in cognitive score, particularly so for the top 25% (26 of 34 pairs, 76%; 95% CI, 59%-89%; P ¼ .003) (Figure 2A ). Corresponding analyses for MADT showed no material influence of cumulative PPI exposure on differences in cognitive score testing of the twinpairs (overall: 54%; 95% CI, 46%-62%, P ¼ .36; top 25%: 39%; 95% CI, 23%-57%; P ¼ .24) ( Figure 2B ). Note that all of the above estimates were adjusted for age and sex by design, and not for other variables included in the individual-based analyses.
Longitudinal Analyses of Decline in Cognitive Score
Individual-based analyses. Compared with the reference group, minor differences were observed in the difference in cognitive score in the twins exposed to PPI in the 2-year follow-up in LSADT, and none of these were statistically significant (Table 3 ). Among individuals with high consumption of PPIs in LSADT, the adjusted mean difference between baseline score and follow-up score was lower than that of nonusers (mean crude score for high PPI use at baseline, 36.6 AE 10.1 and at follow-up, 34.3 AE 12.3 vs for nonuse at baseline, 38.1 AE 10.5 and at follow-up, 37.6 AE 11.3; adjusted delta-difference of 1.22 points; 95% CI, À3.73 to 1.29). In MADT, decline in cognitive scores of individuals exposed to PPI in the 10-year follow-up period was less pronounced from that of nonexposed individuals in all but 1 stratum (ie, cumulative PPI dose of 800 DDD; adjusted deltadifference À1.69; 95% CI, À4.47 to 1.10). In MADT, users with the highest consumption of PPIs (!1600 DDD) had slightly less cognitive decline than nonusers (mean crude score for high PPI use at baseline, 43.4 AE 10.1 and at follow-up, 41.3 AE 9.7 vs for nonuse at baseline, 49.1 AE 10.2 and at follow-up, 46.3 AE 9.9; adjusted delta-difference of 0.94 points; 95% CI, À1.63 to 3.50). Tests for trend were statistically nonsignificant (LSADT, P ¼ .26; MADT, P ¼ .20).
Within-pair analyses. Out of a total of 1296 intact twin pairs with data on cognitive score at baseline and follow-up, 1071 pairs were same sex; of these 743 pairs did not differ with regard to cumulative PPI exposure in the follow-up period. Thus, a total of 328 pairs were included in the follow-up within-pair analyses (MADT, 224; LSADT, 104).
The proportion of twin pairs in which the twin exposed to higher cumulative PPI dose at baseline also was the twin with the largest decline in composite cognitive score did not differ significantly from 50% (null hypothesis) (53 of 104 pairs, 51%; 95% CI, 41%-61%; P ¼ .92). Corresponding analyses restricted to twin pairs with differences in cognitive score belonging to the Proportion of pairs where the twin exposed to higher cumulative proton pump inhibitor dose at baseline also had lower cognitive score. Proportion estimates above 0.5 (red line) compatible with proton pump inhibitor use associated with larger decline in cognitive function. Proportions calculated for all twin pairs and stratified by the magnitude of intrapair difference in cognitive score; note that the strata are not mutually exclusive. P values above each estimate.
top 25% did not materially influence the proportion (11 of 26 pairs, 42%; 95% CI, 23%-63%; P ¼ .56) ( Figure 3A) . Similar results were found in MADT (overall: 111 of 224 pairs, 50%; 95% CI, 43%-56%, P ¼ .94; top 25% with highest difference in cognitive score: 29 of 56 pairs, 52%; 95% CI, 38%-65%, P ¼ .89) ( Figure 3B ). Supplementary analyses including pairs with more marked discordance with regard to PPI use (ie, !100 DDD of PPI in 2-year follow-up in LSADT, and !500 DDD of PPI in 10-year MADT period) did not materially affect results on cognitive decline (Supplementary Figure 2) . In analyses restricted to monozygotic twin pairs, the proportion of pairs where the twin exposed to the higher PPI dose also was the twin with largest decline in composite cognitive score was not higher than expected according to the null hypothesis (Supplementary Figure 3) . Results of supplementary analyses are presented in Supplementary Results and  Supplementary Tables 4-7 .
Discussion
This study is the first to examine the association between long-term PPI use and cognitive decline in a population-based setting. Cognitive scores of more than 7800 middle-aged and older Danish twins at baseline did not indicate an association with previous PPI use. Followup data on more than 4000 of these twins did not indicate that use of this class of drugs was correlated to cognitive decline. These findings were supported by results of within pairs analyses of twins discordant for cognitive scores (baseline) or cognitive decline (follow-up). The magnitude of estimates did not indicate any important association with cognitive function as measured through the composite score, and none of our adjusted estimates reported a statistically significant effect in the longitudinal analyses. In addition, there did not seem to be a clear dose-response effect in any analyses. Overall, the results of this study do not indicate that long-term PPI use correlates with risk for cognitive decline.
The findings of 2 studies in Germany that suggested a possible link between PPI use and increased risk for dementia, 3, 4 have not been replicated in other studies. Another study from Germany, based on primary care data, reported a null association between PPI use and risk of dementia, 22 as did a more recent nationwide study from Finland, where PPI use of community-dwelling newly diagnosed patients with Alzheimer dementia was compared with that of general population control The decline observed in subjects not exposed to PPI during follow-up has been subtracted (Ddifference in cognitive score); follow-up took place 2 years after intake for LSADT and after 10 years for MADT. b Calculated based on prescription register data. c Adjusted for age; sex; education level; body mass index; smoking; alcohol use; physician-diagnosed history of depression; neurologic disorders (stroke, epilepsy, Parkinson disease); thyroid disorders; hypertension; diabetes; and, based on prescription register data, use of medication with possible chronic effect (statins, oral steroids, hormone-replacement therapy, low-dose aspirin, nonsteroidal anti-inflammatory drugs) (<>500 DDD during follow-up) and medications that may impair cognitive function (6-month period before intake) (strong analgesics, anxiolytic, antipsychotic drugs, or antidepressants), and ever use of histamine-2 receptor antagonists. The inference was adjusted for twin pair cluster effects. d Difference in unadjusted cognitive score between baseline and follow-up after 2 years in twins not exposed to PPIs, LSADT: À0.52 (95% CI, À0.85 to À0. 19 ). e Difference in unadjusted cognitive score between baseline and follow-up after 10 years in twins not exposed to PPIs, MADT: À2.80 (95% CI, À3.19 to À2.41).
subjects. 9 A follow-up study from the United States found that subjects taking PPIs on a regular or intermittent basis were slightly less likely to be diagnosed with mild cognitive impairment, or dementia, compared with nonusers of PPIs. 8 The relationship of long-term PPI use with cognition has received less attention. A recent study, based on 13,864 participants in the Nurse's Health Study, reported a null association between long-term PPI use and cognitive function assessed at a single point in time. 11 The present study results are in line with those from this US study and expand current knowledge on the relationship of PPI use and cognition after evaluating for the first time the lack of association between long-term use of PPPs and cognitive decline.
H 2 RA use has also been reported to impact on cognition. Although an early report raised the possibility of a protective effect of H 2 RA use on risk of Alzheimer dementia, 23 subsequent studies did not confirm it. [24] [25] [26] Lockhead et al 11 recently reported poorer cognitive function associated with increasing duration of regular H 2 RA. Smaller cohort studies predating the publication from the Nurse's Health Study 11 reported increased incident cognitive impairment and cognitive decline among users of H 2 RA, compared with nonusers of these drugs. 27, 28 In the present large study, we performed analyses on H 2 RA use post hoc, prompted by the findings of a recent study. 11 Furthermore, H 2 RA use steeply declined in Denmark the past 18 years, because it has been largely replaced by use of PPIs. During the same period, H 2 RA drugs have increasingly been purchased over the counter, 18 and information on these transactions is not available in the prescription registry. Yet, because expenses toward prescribed H 2 RA are partially reimbursed in Denmark, we believe that chronic H 2 RA use is likely captured by the prescription registry. However, these potential shortcomings should be born in mind, when assessing our finding of a lack of association between H 2 RA use and cognitive decline.
This study has several strengths. We used a prescription registry to ascertain drug exposure, which eliminated recall bias. Importantly, for the years covered by the present study, the registry holds information on virtually all (98%) of PPI sold in Denmark. 18 Cognitive assessment at several points in time, enabling a valid measurement of cognitive decline over time, was performed by trained interviewers and based on a battery of recognized tests frequently used in epidemiologic studies. By recruiting participants in a population-based setting we reduced selection forces faced by clinic-based studies. We were able to adjust for multiple confounders, including lifestyle, and education, information frequently not included in register-based studies on PPI use and dementia risk. Because participants were twins, we could perform within-pair comparisons that provided control of genes and common intrauterine and childhood environment factors, factors that may influence cognitive decline.
Several potential limitations need to be considered. Although participation at baseline was generally high (!70%), the participation rate in the follow-up of MADT was lower (62%). This finding may be associated with MADT follow-up being performed at research centers (ie, involving transport), whereas all other study evaluations were performed at participants' homes. Although we cannot rule out some degree of selection in study participation (particularly in MADT follow-up), we believe its impact on our findings to be minor. The follow-up wave of LSADT was performed 2 years after baseline, a time-frame that minimized concerns regarding attrition of the cohort (eg, because of poor health), but, conversely, may have been too short to sufficiently capture long-term declining cognitive trajectories among elderly twins. Our prescription register data were left-censored, corresponding to the creation of the prescription register we used (1995) . The impact of this on assessment of prebaseline cumulative PPI use is probably negligible, because use of this class of drugs before 1995 was limited in Denmark. 18 In spite of these efforts, we cannot preclude the influence of insufficiently measured or unmeasured confounders on our results. Twins study. Proportion of pairs where the twin exposed to higher cumulative proton pump inhibitor dose during followup declined more in cognitive score compared with co-twin. Proportion estimates above 0.5 (red line) compatible with proton pump inhibitor use associated with larger decline in cognitive function. Proportions calculated for all twin pairs and stratified by the magnitude of intrapair difference in cognitive score; note that the strata are not mutually exclusive. P values above each estimate.
